Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients : Results of the Spanish Registry
Franco, Antonio (Hospital General Universitario Dr. Balmis)
Moreso, Francesc (Hospital Universitari Vall d'Hebron)
Solà-Porta, Eulàlia (Parc de Salut MAR de Barcelona)
Beneyto, Isabel (Hospital Universitari i Politècnic La Fe (València))
Esforzado, Núria (Hospital Clínic i Provincial de Barcelona)
Gonzalez-Roncero, Francisco (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Sancho Calabuig, Asunción (Hospital Universitari Doctor Peset (València))
Melilli, Edoardo (Hospital Universitari de Bellvitge)
Ruiz, Juan Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Galeano Alvarez, Cristina (Hospital Universitario Ramón y Cajal (Madrid))
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Historically, donor infection with hepatitis-C virus (HCV) has been a barrier to kidney transplantation. However, in recent years, it has been reported that HCV positive kidney donors transplanted into HCV negative recipients offer acceptable mid-term results. However, acceptance of HCV donors, especially viremic, has not broadened in the clinical practice. This is an observational, multicenter, retrospective study including kidney transplants from HCV positive donors into negative recipients reported to the Spanish group from 2013 to 2021. Recipients from viremic donors received peri-transplant treatment with direct antiviral agents (DAA) for 8-12 weeks. We included 75 recipients from 44 HCV non-viremic donors and 41 from 25 HCV viremic donors. Primary non function, delayed graft function, acute rejection rate, renal function at the end of follow up, and patient and graft survival were not different between groups. Viral replication was not detected in recipients from non-viremic donors. Recipient treatment with DAA started pre-transplant avoids (n = 21) or attenuates (n = 5) viral replication but leads to non-different outcomes to post-transplant treatment with DAA (n = 15). HCV seroconversion was more frequent in recipients from viremic donors (73% vs. 16%, p < 0. 001). One recipient of a viremic donor died due to hepatocellular carcinoma at 38 months. Donor HCV viremia seems not to be a risk factor for kidney transplant recipients receiving peri-transplant DAA, but continuous surveillance should be advised.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Graft outcome ; Hepatitis C virus ; Hepatocellular carcinoma ; Kidney transplantation ; Viremic donor
Published in:	Journal of clinical medicine, Vol. 12 (february 2023) , ISSN 2077-0383

DOI: 10.3390/jcm12051773
PMID: 36902560

11 p, 1.5 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles